Medical Tomography News
-
Bayer driving innovation in radiology with new research across the portfolio presented at ECR
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...
By Bayer AG
-
Bayer completes acquisition of Blackford Analysis Ltd.
Closing follows announcement of acquisition on January 18, 2023 Acquisition bolsters Bayer’s position in digital medical imaging Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today announced that the company has completed the acquisition of the global strategic ...
By Bayer AG
-
Ultravist by Bayer now approved for contrast-enhanced mammography in EU
Ultravist-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure CEM is emerging modality combining digital mammography with the administration of a contrast agent Strategically expands Bayer’s portfolio in breast imaging, including contrast agents and injectors Bayer announced today that its ...
By Bayer AG
-
Bayer acquires Blackford Analysis Ltd. bolstering the company’s position in digital medical imaging
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today ...
By Bayer AG
-
Prof. Krestin Joins Fluidda’S Board of Directors
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
By Fluidda
-
Adiposs starts clinical development of its flagship product ImageBAT
Adiposs SA, a Geneva-based biotech company developing medical imaging products, has successfully launched its phase 1 clinical trial on August 10, with the dosing of the first human subjects with ImageBATTM, its first-in-class product for brown fat imaging. Adiposs has initiated the clinical development of its flagship imaging product, ImageBATTM. The primary objective of the IBT001 phase 1 ...
By Adiposs
-
electroCore, Inc. Announces Study of gammaCore Sapphire for the Treatment of Post-COVID Syndrome
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days ...
-
Bayer expands Radiology Business into AI Market with Calantic Digital Solutions
AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow Market introduction to start in US and several European countries Strategically complements Bayer’s comprehensive portfolio of contrast media, fluid delivery ...
By Bayer AG
-
Saranas Announces Peer-Reviewed Publications Highlighting Accuracy And Clinical Utility Of Early Bird Bleed Monitoring System
Saranas, Inc., developer of the Early Bird® Bleed Monitoring System for the monitoring and early detection of internal bleed complications during endovascular procedures, announced the online publication of two peer-reviewed articles highlighting the system’s accuracy and performance. The publications provide evidence of the Early Bird’s reliability to detect the early onset and ...
-
Thoma Bravo Completes Strategic Growth Investment in Circle Cardiovascular Imaging
Thoma Bravo, a leading software investment firm, today announced the completion of its strategic growth investment in Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions. Circle CVI is the leading provider of AI-based cardiac imaging and reporting solutions, including cardiac MRI ("CMR") and cardiac computerized tomography ("CT") imaging ...
-
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable embolic therapies, announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in collaboration ...
-
Circle Cardiovascular Imaging Announces Strategic Growth Investment from Thoma Bravo
Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions, today announced a strategic growth investment from Thoma Bravo, a leading software investment firm. Thoma Bravo's partnership is expected to drive future investment in product innovation, extend Circle CVI's market leadership position and fuel future growth. Financial terms of the transaction ...
-
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate ...
-
Another good news for Deep01! Taiwan`s first AI product obtained marketing approval from Japan`s FDA
DeepCT - Intracranial Hemorrhage (ICH) AI Detection Software - developed by Taiwan's high-profile AI start-up team Deep01 - has obtained the marketing approval of Japan's PMDA, which is the first deep learning software officially licensed by Japan in Taiwan , marking a new milestone in Taiwan's AI medical output. Japan has the world's most aging population, and with advanced medical development, ...
-
Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be a catalyst for non-invasive image, revolutionizing the way patients with coronary artery disease are diagnosed and treated. In a highly anticipated document published online yesterday in Circulation and the Journal of ...
By Elucid
-
Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies at the virtual Society of Cardiovascular Computed Tomography (SCCT) 16th Annual Scientific Meeting. The studies ...
By Elucid
-
Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)
Computed tomography angiography (CTA) has been increasingly used in the diagnosis of vascular disease and its a modality that offers many potential clinical benefits. The question is, how to actualize that benefit and get the most our of the modality. Elucid has developed an artificial intelligence software that might just answer that question. How AI Can Improve CTA Analysis ...
By Elucid
-
Profound Medical Receives FDA HDE Approval for Sonalleve
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of ...
-
Smiths Detection Achieves Major Manufacturing Milestone in Support of the TSA Advanced Technology X-ray Program
Smiths Detection Inc. (SDI) has announced it has successfully manufactured and shipped the 200th Computed Tomography (CT) 3-D Scanner from its Americas Headquarters located in Harford County, MD. The CT scanner marks a major milestone in advancing Transportation Security Administration’s (TSA) initiatives and is the result of SDI’s ongoing manufacturing during the COVID 19 crisis as ...
-
Smiths Detection win Red Dot Design award for the HI-SCAN 6040 CTiX graphical user interface
Smiths Detection were recently awarded a prestigious Red Dot award for the intuitive design of the graphical user interface (GUI) of our computed tomography (CT) checkpoint scanner HI-SCAN 6040 CTiX. Once a year the international Red Dot design competition awards excellence in the areas of product design, communication design, and design concepts. CT systems have been introduced to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you